CENTRO DE INMUNOLOGIA MOLECULAR (20240374695). VACCINE COMPOSITIONS DEPLETING HEMATOPOIETIC GROWTH FACTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES simplified abstract

VACCINE COMPOSITIONS DEPLETING HEMATOPOIETIC GROWTH FACTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES

Organization Name

CENTRO DE INMUNOLOGIA MOLECULAR

Inventor(s)

[[:Category:Agustín Bienvenido Lage D�vila of La Habana (CU)|Agustín Bienvenido Lage D�vila of La Habana (CU)]][[Category:Agustín Bienvenido Lage D�vila of La Habana (CU)]]

Danay Saavedra Hernandez of La Habana (CU)

Oscar Otero Alfaro of La Habana (CU)

[[:Category:Gisela María Su�rez Formigo of La Habana (CU)|Gisela María Su�rez Formigo of La Habana (CU)]][[Category:Gisela María Su�rez Formigo of La Habana (CU)]]

Gertrudis Rojas Dorantes of La Habana (CU)

Jesus Ramón Galvez Valcarcel of La Habana (CU)

[[:Category:Armando L�pez Medianilla of La Habana (CU)|Armando L�pez Medianilla of La Habana (CU)]][[Category:Armando L�pez Medianilla of La Habana (CU)]]

[[:Category:Dayana P�rez Mart�nez of La Habana (CU)|Dayana P�rez Mart�nez of La Habana (CU)]][[Category:Dayana P�rez Mart�nez of La Habana (CU)]]

[[:Category:Nuris Led�n Naranjo of La Habana (CU)|Nuris Led�n Naranjo of La Habana (CU)]][[Category:Nuris Led�n Naranjo of La Habana (CU)]]

[[:Category:Karla Pereira Y��ez of La Habana (CU)|Karla Pereira Y��ez of La Habana (CU)]][[Category:Karla Pereira Y��ez of La Habana (CU)]]

Alexa Silva Sosa of La Habana (CU)

Dasha Fuentes Morales of La Habana (CU)

VACCINE COMPOSITIONS DEPLETING HEMATOPOIETIC GROWTH FACTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240374695 titled 'VACCINE COMPOSITIONS DEPLETING HEMATOPOIETIC GROWTH FACTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES

The present invention relates to therapeutic vaccine compositions that can induce an autoimmune reaction against haemopoietic growth factors like G-SCF and/or GM-CSF, which are bound to other molecules or fragments through chemical conjugation or fusion. These vaccine compositions are particularly useful for treating inflammatory diseases where there is a pathological increase in circulating neutrophils.

• The invention involves therapeutic vaccine compositions that target haemopoietic growth factors through chemical conjugation or fusion.
• These vaccines can trigger an autoimmune reaction against G-SCF and/or GM-CSF, which are crucial for the production of neutrophils.
• The compositions are designed to treat inflammatory diseases characterized by an abnormal increase in circulating neutrophils.
• By targeting these growth factors, the vaccines aim to regulate the production of neutrophils and alleviate symptoms associated with inflammatory conditions.
• The innovation opens up new possibilities for treating autoimmune diseases and other conditions where haemopoietic growth factors play a significant role.

Potential Applications: - Treatment of inflammatory diseases - Management of autoimmune conditions - Regulation of neutrophil production in various medical conditions

Problems Solved: - Addressing the overproduction of neutrophils in inflammatory diseases - Targeting haemopoietic growth factors for therapeutic purposes

Benefits: - Potential for more targeted and effective treatment of inflammatory diseases - Regulation of neutrophil levels to manage symptoms and improve patient outcomes

Commercial Applications: Title: Therapeutic Vaccine Compositions Targeting Haemopoietic Growth Factors Description: This technology has the potential for commercial applications in the pharmaceutical industry for the development of novel treatments for inflammatory and autoimmune diseases. The market implications include the possibility of introducing more targeted and efficient therapies for these conditions.

Questions about Therapeutic Vaccine Compositions Targeting Haemopoietic Growth Factors: 1. How do these vaccine compositions differ from traditional treatments for inflammatory diseases?

  These vaccine compositions target specific haemopoietic growth factors to induce an autoimmune reaction, offering a more targeted approach compared to conventional treatments that may have broader effects on the immune system.

2. What are the potential implications of targeting haemopoietic growth factors for the treatment of autoimmune diseases?

  Targeting haemopoietic growth factors opens up new possibilities for managing autoimmune conditions by regulating the production of neutrophils, which play a crucial role in the immune response.

Original Abstract Submitted

the present invention is related to the fields of biotechnology and medicine. particularly, it describes therapeutic vaccine compositions able to produce an autoimmune reaction against haemopoietic growth factors such as g-scf and/or gm-csf bounded to other molecules or a fragment thereof by chemical conjugation or fusion. such vaccines compositions are useful for the treatment of inflammatory diseases, especially wherein a pathological increasing of the circulating neutrophils occurs.